CDKN2A and astrocytoma (excluding glioblastoma): Several recent studies also confirm the present of copy number alterations, particularly CDKN2A/B loss and CDK4 amplification, clinically conferring poorer prognosis in IDH-mutant astrocytomas (137–141).